Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13352364 | 0.86 | OPRK1 (0.76) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| Halazepam SCHEMBL29375979 | 0.86 | OPRK1 (1.00) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| Halazepam SCHEMBL78995 | 0.86 | OPRK1 (1.00) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL7858451 | 0.85 | HDAC3 (0.63) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL7541208 | 0.82 | GABRA1 (0.68) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL5656161 | 0.82 | OPRK1 (0.64) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL27562818 | 0.81 | NPSR1 (0.78) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL8672792 | 0.80 | SMN1; SMN2 (0.67) | NPSR1GAAHTTGPR55GABRA1 | |
| SCHEMBL8851595 | 0.80 | GABRA1 (0.68) | NR1I2ADORA3OPRM1OPRK1NPSR1 | |
| SCHEMBL23560411 | 0.79 | GABRA1 (0.63) | NR1I2ADORA3OPRM1OPRK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092769-A1 | TRICYCLIC AND TETRACYCLIC SYSTEMS ACTING UPON THE VASCULAR AND CENTRAL NERVOUS SYSTEMS | CENTRO DE INVESTIG Y DESARROLLO DE LOS MEDICAMENTOS CIDEM (CU) | 2019-03-28 | — | — | US | disclosed |
| US-10138231-B2 | Tricyclic and tetracyclic systems acting upon the vascular and central nervous systems | Centro de Investigacion Y Desarrollo de... (CIDEM) (CU) | 2018-11-27 | — | — | US | disclosed |
| US-9315497-B2 | Tricyclic and tetracyclic systems with activity on the central nervous and vascular systems | Centro de Investigacion Y Desarrollo de . . . (CIDEM) Laboratorio de Sintesis Organica de La Facultad . . . (CU) | 2016-04-19 | — | — | US | disclosed |
| US-20140275042-A1 | TRICYCLIC AND TETRACYCLIC SYSTEMS ACTING UPON THE VASCULAR AND CENTRAL NERVOUS SYSTEMS | VERDECIA REYES YAMILA (CU) | 2014-09-18 | — | — | US | disclosed |
| EP-1641781-B1 | Benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2487174-A2 | TRICYCLIC AND TETRACYCLIC SYSTEMS WITH ACTIVITY ON THE CENTRAL-NERVOUS AND VASCULAR SYSTEMS | Centro de Investigación y Desarrollo de Medicamentos (CIDEM) (CU) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202791-A1 | Tricyclic and Tetracyclic Systems with Activity on the Central Nervous and Vascular Systems | CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS (CIDEM) (CU) | 2012-08-09 | — | — | US | disclosed |
| EP-1606286-B1 | BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1641423-B1 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0776208-A4 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0776208-A4 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| CN-1158568-A | 2,3-dihydro-1-1(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | MERCK & CO INC (US) | 1997-09-03 | — | — | CN | disclosed |
| US-5658901-A | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658901-A | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0776208-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776208-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996005839-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996005839-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092769-A1 | TRICYCLIC AND TETRACYCLIC SYSTEMS ACTING UPON THE VASCULAR AND CENTRAL NERVOUS SYSTEMS | TBXAS1, QDPR, GABBR1 | NR1I2 86/4885ADORA3 431/4885OPRM1 171/4885 |
| US-20120202791-A1 | Tricyclic and Tetracyclic Systems with Activity on the Central Nervous and Vascular Systems | CACNA1I, CACNA1G, CACNA1D | NR1I2 151/4885ADORA3 426/4885OPRM1 283/4885 |
| US-10138231-B2 | Tricyclic and tetracyclic systems acting upon the vascular and central nervous systems | TBXAS1, GABBR1, BDKRB2 | NR1I2 101/4885ADORA3 298/4885OPRM1 131/4885 |
| US-20140275042-A1 | TRICYCLIC AND TETRACYCLIC SYSTEMS ACTING UPON THE VASCULAR AND CENTRAL NERVOUS SYSTEMS | TBXAS1, GABBR1, BDKRB2 | NR1I2 101/4885ADORA3 298/4885OPRM1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.